Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder Article

Wozniak, J, Mick, E, Waxmonsky, J et al. (2009). Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder . JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 19(5), 539-545. 10.1089/cap.2009.0042

cited authors

  • Wozniak, J; Mick, E; Waxmonsky, J; Kotarski, M; Hantsoo, L; Biederman, J

authors

abstract

  • Background: The aim of this study was to test the efficacy and safety of olanzapine+topiramate versus olanzapine monotherapy in the treatment of bipolar disorder (BPD) and treatment-attendant weight gain in children and adolescents. Method: Subjects (N=40) were outpatients of both sexes, 6-17 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of BPD (manic, hypomanic, or mixed) and Young Mania Rating Scale (YMRS) total score of >15 treated over 8-week periods in two partially concurrent open-label trials with olanzapine (n=17) or olanzapine+topiramate (n=23). Results: Subjects in both groups experienced a statistically significant reduction in YMRS scores after 8-week, open-label treatment with olanzapine (baseline YMRS=26.7±9.5; end-point YMRS=18.2±12.5, p=0.04) and olanzapine+topiramate (baseline YMRS=31.3±7.9; end-point YMRS=20.4±11.4, p=0.04). There was no difference in response between the two groups based on YMRS or Clinical Global Impressions-Improvement (CGI-I) scores. Adverse events were few and mild and similar between the two groups, with the exception of weight gain. The weight gain in the olanzapine group was 5.3±2.1kg and the weight gain in the olanzapine+topiramate group was statistically significantly lower, 2.6±3.6kg. Conclusions: Augmentation of olanzapine with topiramate resulted in a reduced weight gain over the course of an 8-week, open-label trial when compared with olanzapine treatment alone, but did not lead to greater reduction in symptoms of mania. © 2009, Mary Ann Liebert, Inc.

publication date

  • October 1, 2009

published in

Digital Object Identifier (DOI)

start page

  • 539

end page

  • 545

volume

  • 19

issue

  • 5